| Development of the sodium-glucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with Type 2 diabetes mellitus. | |
| | |
MedLine Citation:
|
PMID: 22111852 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Dapagliflozin is a highly selective sodium-glucose co-transporter 2 inhibitor developed for the treatment of Type 2 diabetes mellitus. Its inhibition of sodium-glucose co-transporter 2 blocks glucose reabsorption in the proximal tubule of the kidney, increasing renal glucose excretion via the urine, resulting in reduction of glycated hemoglobin, fasting plasma glucose and postprandial plasma glucose in patients with Type 2 diabetes mellitus. The pharmacokinetics and pharmacodynamics of dapagliflozin are suitable for once-daily dosing. Dapagliflozin improves glycemic control when used as monotherapy and when used in combination with other antidiabetic treatments. Throughout all phases of clinical studies, dapagliflozin was generally well tolerated. Increased events suggestive of urinary tract and genital infections have been reported; most resolved with conventional treatment. Unexpected numerical imbalances between dapagliflozin and comparator were noted for breast and bladder cancers. The potential for increased cancer risk with dapagliflozin needs to be further assessed. |
| | |
Authors:
|
John E Gerich; Arnaud Bastien |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Expert review of clinical pharmacology Volume: 4 ISSN: 1751-2441 ISO Abbreviation: Expert Rev Clin Pharmacol Publication Date: 2011 Nov |
Date Detail:
|
Created Date: 2011-11-24 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101278296 Medline TA: Expert Rev Clin Pharmacol Country: England |
Other Details:
|
Languages: eng Pagination: 669-83 Citation Subset: IM |
Affiliation:
|
University of Rochester, School of Medicine, Rochester, NY 14642, USA. johngerich@compuserve.com. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia...
Next Document: Sipuleucel-T: a therapeutic cancer vaccine for the treatment of castration- or hormone-refractory pr...